Okay, perfect. We'll start. Good morning, everyone in the room. Thank you for joining this session of the Morgan Stanley Global Healthcare Conference. I am Thibault Boutherin. I am Co-head of the European Pharma Equity Research Team based in London. Before we start the session, I need to refer to important disclosures. Please see the Morgan Stanley Research Disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative. For this session with Alvotech, I am delighted to have with me Balaji Prasad, Chief Strategy Officer of the company. Thank you for joining us today. We'll shortly go to a Q&A. But before that, Balaji, do you want to start with some introductory comments on Alvotech and the outlook of the company?
Sure. Thank you, Thibault. Firstly, let me thank Morgan Stanley for inviting us. It's been a very productive day of conference meetings yesterday for us, and delighted to be participating this fireside. So thank you, Thibault, for doing that. About Alvotech, so we've had a journey now of the last 12 years. We've started selling in the U.S. from last year with biosimilar Humira and this year with biosimilar Stelara, Simlandi last year, respectively. We are at the edge of what we believe is the next phase of our growth trajectory with a few key approvals that we are awaiting. So that would take us from, like, a two-product company, primarily to a five, six-product company by next year. And we are really excited about it, right?
As we see today with the approvals for biosimilar to Eylea, Prolia, Xgeva, and Simponi/Simponi Aria, we are really excited to be standing at this threshold and to expand our offerings to the public for improving healthcare and at a lower cost, right? Really excited about it and looking forward to these and to our next phase of growth. Over to you. Thank you.
Amazing. Thank you for the introduction. So, just maybe very quickly before we move on, to actually talking about the business, just want to mention the current U.S. policy context with tariffs. So obviously, your business model is very unique. You out-license products to partners who then do the commercialization. So in that context, how, you know, do U.S. pharma tariffs impact you, in any way? Does it have an influence on your recent discussions with partners?
So I like this, getting the easy questions out of the way, right? Luckily for us, it's actually a relatively easier viewpoint for us to have from it. So as you know, all of our R&D and manufacturing is based in Iceland. So everything we sell in the U.S., it's exported from Iceland to here. And the way the setup is, is that we manufacture, package, and then our partners pick it up from us. And our partners are responsible for all of the tariffs or any duties or anything else that's, that they have to pay, right? Stepping aside from that model, just on the tariffs itself, right? As things stand today, there have been multiple tariffs that have floated around. But as we sit today, it looks like there's possibly a 15% tariff on pharmaceutical goods and with a possible 0% carve-out for biosimilars and generics.
So we do not expect to pay any tariffs on that if this comes out of the case. But beyond that, we even if you think about it, if we are looking at tariffs in the double-digit rate, for instance, as we have said before, there's no material impact for us, right? We saw that with partners paying for it. And so for us, in terms of actual impact, it's limited. But if we get to a 0% tariff rate on biosimilars and generics, that's the best case for us, you know, outcome for us.
Fantastic. I want to maybe talk about the 2025 outlook, you know, the split between recurring revenues and milestones and the bridge to the 2028 guidance. So for this year, you provided a guidance for $600 million-$700 million of revenues with a bit more than half coming from product revenues, and a bit less than half from milestones. Is this year particularly strong on the milestone side? How should we think about the split between recurring revenues and milestones beyond this year?
Sure. The milestone story is the natural part of our evolutionary process as a company. We were milestone-heavy in the start where we didn't have commercial products in the market. So all of our revenues were coming from milestones. And as we progress through, milestones will still be substantial on an absolute basis. But we would want it to be for the relative part of the proportionate to our overall revenues. Milestones will go down. We will see more and more royalties, yeah? That's a natural part of our evolution. Before I get into the guidance, I just want to make clear that 2028, I think we've said $1.5 billion. It's, we will not call it a guidance. It's our aspirational target. I think I can see both upside scenarios to this, downside scenarios to this.
But I think if we do what we are doing, we should be somewhere in that ballpark. And of course, to come to a more precise guidance for 2028, we'll probably be doing at the early phase of 2028 or somewhere around that time, right? Coming to the 2025 guidance, $600 million-$700 million. So we're looking to generate at least $600 million of revenues, at least $200 million with EBITDA. And within that, of course, as you called out, milestones is a fairly chunky part of it. And that is linked to multiple things with regard to milestones on commercial achievements, milestones and improvements. So there are quite a few components to this milestone. And as we called out, we are at the cusp of multiple approvals, potential approvals that we are looking forward to eagerly.
As and when these approvals come through in Q4, we should be talking these milestones. That really forms the base of our outlook for the year.
Okay. That's very clear, and now I want to touch a bit on your product portfolio and the current products on the market. You have two products on the U.S. and ex-U.S. market, as you mentioned, the biosimilar Humira, and Stelara. Maybe if we start with biosimilar to Humira, can you touch a little bit on how the US market is developing, how you see the performance between the private label, but also on the, you know, outside of the private label segments, maybe starting here?
Yeah. Biosimilar Humira market, it's a very interesting one because that's one of the first major pharmacy-reimbursed biosimilars market to form. We got into the market in early 2024. It's now been around six to seven quarters for us. And we are very excited with how we have progressed through this, right? Last year, we had a pretty substantial amount of units sold, as you know, with the purchase orders we commented on. And this year, again, we've had a pretty good first half. And as we look at the market, again, very interesting to answer it. I mean, private label deals did form a meaningful part of it. But then again, there is various ways to skin the cat. And private label deals are one such way with the biosimilar Humira market.
I can contrast this with biosimilar Stelara, where we have said that we are not actively pursuing private label deals. We see better economics for us with other forms of contracts, right? Within the market at this point of time, we had called out a few months ago that we would expect the biosimilar market overall in Humira to be around 50%. A recent update from IQVIA, I think it was last week, confirmed that it is at around 50%. We are very happy that we are the second largest, we have the second largest market share both as a function of the formulary-based and the private labels. As of July, we are the second largest market share. And I also want to call out our commercial partner Teva, who's been doing a phenomenal job, especially on the formulary side.
We have full confidence in them to continue to drive this growth on the formulary side.
Okay. Amazing. That's very clear and outside of the U.S., you know, how is the situation progressing here? Are you and your partner in the, you know, ex-U.S. gaining share? And how should we expect the growth of this STADA development in the coming years?
Yeah. I'm thankful to you for asking that question because Alvotech is definitely not a U.S.-only story. We are a global story. We are selling in 70 to 90 countries. We have about 20 commercial partners. We plan to sell in a few more countries with 90 countries that we have partnerships for, and Europe is a very substantial part of our growth story too, right? We have exceptional partners with STADA and Advanz and all. So with biosimilar Humira, again, we see this as a long-term growth story. We will see we expect to see volume growth coming through in multiple geographies as we expand our presence. We have dominant market share in many of these countries. We'll be launching in a few more.
And as we think about even the U.S. dynamics, like we've sold good, we expect overall to continue to see this volume growth. And we'll see how pricing evolves. Sometimes it follows a natural curve of the product lifecycle. But we are eagerly looking forward to continue to drive this growth.
Amazing. And, can you also give us some update on, you know, the situation for Stelara, as well? Yeah, yeah, so for Stelara, maybe similar questions.
Mm-hmm.
You know, between, you know, the evolution of the situation in U.S. versus Express.
Yeah. So it's been around four or five months since we launched Selarsdi, biosimilar to Stelara in the U.S.. As I said, it's the market's still forming. It's still in an early stage. That said, at around this point, the market's definitely a bit more advanced than what the biosimilar Humira market looked like, where it was around 4%-5% conversion. We are at around 13%-14% conversion. And we continue to win newer contracts. I mean, we have, as I said, there are multiple ways to skin the cat. And we are looking at unbranded deals. We're looking at multiple other options.
And we called out in our Q2 call that we are not actively pursuing private label deals because we think that from Alvotech perspective and where we want to ensure that we have a sustainable, profitable business model, there are deals, other forms of deals that we would also want to pursue, okay? So that's in the U.S.. We'll look forward to driving this. And we'll provide an update as we come towards the end of the year. In Europe, it has definitely been a very strong success story for us. We launched in multiple major markets in Europe, Germany, France. And in most of the key markets, we are either number one or number two in terms of market share. So we're extremely happy with how our partners have succeeded commercially. And we expect that would continue to be the case.
Japan is another good, strong growth story for us, where we launched it in Japan and Canada, and we are seeing market share traction in these geographies too, and we expect that to continue to be the case, so continuing to reiterate that our model of global growth continues to deliver across not just the U.S., but all major geographies.
That's clear, and if we take a step back and, and we look at the U.S. biosimilar market.
Mm-hmm.
Which has been evolving a lot since, you know, the launch of Humira for the pharmaceutical-based biosimilars. It's interesting that you decided not to go private label with Stelara. Can you just tell us sort of, you know, how you see the U.S. biosimilar landscape evolving in the future, and that decision you took with Stelara, is it something that you expect will be replicated in the future, or it's sort of a case-by-case decision you're going to make?
Yeah. The U.S. biosimilars market, since the first biosimilar launched in 2015, has gone through multiple phases. I mean, there's a whole 2015 to 2019 phase where biosimilars really struggled to achieve traction. 2019, pegfilgrastim was one of the first ones which actually achieved meaningful traction there, on the buy-and-bill side. And then, Humira market, 2023 onwards, that was a different case right now for the pharmaceutical side. And, as we stand today, two years post the biosimilar Humira market went biosimilar way, we are standing at a 50% conversion. And this conversion will continue to expand further. So we've had two case studies now with the pharmaceutical side, with Humira and Stelara.
Now, the next set of launchers are back to the buy-and-bill model, where since you asked about private label deals, we don't think private label deals will matter meaningfully on the buy-and-bill side. There are different aspects of buy-and-bill where economics for the clinicians or the clinics, like ASP reimbursement, those would drive having a strong brand positioning with maybe associated patient services as the case may be. Those would drive. And we have confidence in our commercial partners. So for Prolia and Xgeva, Dr. Reddy's, and for Simponi and Eylea, it's Teva. We have confidence in our commercial partners that they will deliver. I want to reiterate again that our choice of a commercial partner is really like going for the strongest local player. It's not a global partnership.
As in, we won't tie up with one company for a global partnership, but see which is a dominant company in each geography commercially and tie up with them. And, that way, they have Teva as really the, the leading company now for us.
Okay. Amazing. And so you just mentioned a bit about your near-term pipeline. You're going to launch several assets in the future.
Mm-hmm.
including biosimilars of denosumab, so Prolia, Xgeva, Simponi, Eylea. You know, which kind of these opportunities are you and the organization most excited about?
So that's like me asking you which of your biosimilars are you most excited about, right? So all of these opportunities are equally exciting. That said, I've called out that Prolia, we expect it to be a competitive market. We think that where we are, but it's still going to be a important, very important asset for us. Coming next to Eylea, again, we would expect to be one of the first. We said we'll be second to market, but we'll be one of the early entrants in with Eylea for sure. It is an important opportunity, especially as the anti-VEGF market opens up. I mean, we saw a recent case a few years ago, and now Eylea coming through. We expect to see the physicians definitely opting for biosimilars and the conversion to happen. Eylea is going to be an important asset for us.
Also, because we have both forms of presentations, both the PFS and vial forms of presentation, right? Now, this plus our future anticipated launch with Eylea, high-dose that we are expected to bring to the market in a couple of years, I think these two would form a strong combination in the anti-VEGF market for us. Then coming to Simponi, again, very excited about it because we'll expect to be the first to market. And we expect to be the first to market for some time. So it's going to be a limited competition opportunity for us. And as you know very well, Teva, economics is a thing, especially if you're a sole biosimilar or you're one of the early ones. Definitely, it's an attractive asset. And the market size overall is also very attractive, so.
Amazing. And if we zoom a little bit on Eylea, you know, we see biosimilar launching first on the low dose, Regeneron in the U.S. and, and Bayer ex-U.S. are working very hard, trying to switch as much patients as they can to the high dose. So how do you see sort of that market, evolving? And, yeah, if you can tell us a little bit about, your ambition for the high-dose formulations.
Yeah. It's still in the clinical development phase. So it's probably early days to really call out how we see the market develop itself, as we come to the market. We'll wait for approval. And then we will give better indications around when we expect to launch. As I said, we expect to launch as soon as possible post approval. And it's a buy-and-bill market. It's one of our first buy-and-bill markets. So we will be on top of it from a commercial aspect. But getting into how the market itself would shape up post our approval, I think it's a bit premature at this point of time. But we'll definitely give more color on it when the time's right.
That's very clear. And beyond these launches, when we think about your long-term pipeline, you have obviously a very broad biosimilar pipeline. So, you know, can you talk a little bit about how we see going to unfold over the next few years, you know, sort of cadence of launches, and how you see the portfolio evolving, you know, in the mid-long term?
Yeah. We had our first set of launches. And then over the next, after this phase, we have another phase of approvals coming through. We have, we'll be awaiting approvals to biosimilar Entyvio, and high-dose Eylea as a call-out, and biosimilar Xolair. Those would be the next three approvals that we would look forward to in the 2027, 2028 timeframe. Beyond 2028, we would also be looking forward towards biosimilars to Keytruda, biosimilar to the Dupixent, amongst others, biosimilar Cimzia. Some of these are like exclusive assets, like, Entyvio is something where we expect it to be a limited competition market. Cimzia, a very attractive asset for us. We expect it to be a limited competition product. I mean, as far as we know at this point, there's only one other developmental project on Cimzia. So these would be limited competition opportunities, right?
And then beyond this, we have another six to seven disclosed assets, so around 14 disclosed assets in total. And then another 14 assets, 14 cell lines that we can bring to development. So 28 assets in our pipeline that we can bring to development over the next 10 years. And this would be like forming the growth trajectory for us for the foreseeable future and the distant future too. We're very excited. This is one of the most comprehensive biosimilar pipelines globally. And if not, we believe it's one of the most valuable pipelines.
Okay. That's great. And just coming back on, you mentioned Cimzia. Coming back o n the Xbrane deal, you acquired the R&D organization.
Mm-hmm.
Of Xbrane and including that, Cimzia biosimilar. So if you can come back on this deal and what it brings, beyond the Cimzia biosimilar.
Yeah. Xbrane was a fantastic asset for us. I'll probably summarize it into three points, right? It was a great asset. We got in R&D. We got in Cimzia asset. We got in around 40 experienced R&D personnel along with this asset, right? And it was great. Point two, Cimzia itself just more than justifies the acquisition of it or more than it recoups the cost for us. We have just signed an out-licensing deal with Advanz Pharma for Europe for Cimzia. We are getting calls. We are fielding calls for the U.S. market and the ROW markets for partnering on Cimzia. Why? Because it's a unique asset in the immunology space. It's one of the rare ones which is approved for rheumatoid arthritis and other chronic immunology conditions for women of childbearing age.
So it's a very unique asset that we were smart enough to identify. Our team was lucky enough to get the deal done, yeah? Point three, as I said, we are looking to expand our R&D filings programs from around three to four a year to four to six a year. Xbrane was one of the reasons that allows us to make this possible because it expands our R&D developmental capability or bandwidth. We plan to take the Swedish operations from 40- 200 FTEs over the next couple of years. So we definitely have greater ambitions for Xbrane and how we can leverage and capitalize on this and expand our number of assets that we can bring into the market at a more rapid pace.
Okay. That's great. And on the biosimilar Cimzia in particular, can you remind us the timeline of this program when you think you could launch the asset? Because I think IP is not going to be the limiting factor, right? It's going to be depending on how fast you can develop the asset.
Yeah. It's not an asset that we called out as something that, we would launch before 2028. So it's, it's going to be some time after that. As and when we complete the developmental part of it and we have better visibility on the timelines, we'll definitely announce it. But it's at least for the time being, what I would like you to take away with this is that, in our, 2028 aspirational goal of around $1.5 billion, Cimzia does not form a part of it.
Okay.
It's excluding it.
Very clear. And one thing that's been quite remarkable on the biosimilar industry, you know, over the recent past was we started to see players sort of skipping or downsizing some Phase III programs on their assets, based on feedback from the EMA and the FDA, basically, you know, sort of lightening the regulatory requirements to get biosimilars approved. So it seems that, you know, there is a sort of real opportunity to streamline biosimilar developments.
Yeah.
So what does it mean, you know, in terms of, sort of development timeline and cost, and how are you thinking about this?
Yeah. The biosimilar developmental timelines and costs has evolved over the years, right? When I was looking at biosimilars for the first time, as an analyst, many years ago, and we were thinking of speaking about biosimilar development costs being $300 million, that kept a lot of companies, especially companies who are not serious about biosimilars out of it, out of this, right? And then as things evolved, there have definitely been some economies that have dropped some costs down. But we are very excited about this development because, A, it brings down the cost of development. We can advance more programs into the developmental phase. B, it also compresses the timeline. And what it also means on the other side is that the FDA is not just going to reduce these requirements and not be more stringent on others.
There's going to be greater PK data, which is needed. There's going to be greater focus on CMC. And we as a company pride on our quality controls and our manufacturing process. So we think that this definitely brings us a competitive advantage. Earlier, I said that we plan to go from three to four products a year to four to six projects. And Xbrane makes it feasible. And this lowering the cost of development also makes it feasible for the handful of biosimilar companies globally.
Okay. Very clear. You know, however, you know, when we think about development costs, you know, being sort of lowered, definitely, you know, lower cost, lower accelerated timeline, but also probably means lower barriers to entry. So how do you think, you know, about the trade-off between, you know, the opportunities provided in terms of expanding your pipeline versus the risk of seeing, you know, more competitors for each asset?
Yeah. I'm glad you asked this, because I think there are multiple differentiating factors. I mean, this is a question that I get often where investors, some investors could mix up the biosimilars industry for the generics industry. Very different. Like, the barriers to entry, especially with technology, with access to resources, with knowledge, with capital, is significantly higher on the biosimilar side because ultimately, it's biologics that we're developing. Let me just remind you that Alvotech itself, we have invested over $2 billion in this facility over the last 10 years. This, that's not going to change. The required investment, overall, that's not going to change.
Your clinical cost may come down, as and which is why I don't think that this is going to open the floodgates for newer companies to rush in saying that, "Hey, biosimilar costs of development has gone down from $200 million to possibly $100 million." So let's jump in. I don't think so. I don't think that's going to be the case. Could it mean that biosimilar companies could expand their pipeline? We, we definitely plan to expand it. And, we, we will see some of our more serious, peers also doing the same.
Okay. And maybe one thing that's been emerging in the biopharma industry, I think more and more over the last few years, has been the emergence of China in terms of, you know, a source of innovation for large pharma. But definitely, you know, the sort of technology, you know, modalities they have has progressed very, very quickly. What does it mean for biosimilars and what role do you see China playing in the biosimilar landscape, as a originator of biosimilars in the next few years?
Yeah. Incidentally, I read your report on China and its biotechnology from the team, the report that the Global Pharma team put out last week, I think. It's a good report. All right. So China, especially, I think, as we think about it, I think it's a meaningful bio contender. On the biologics side, we have one or two companies that we do see. And in terms of the market shape and formation itself, I think what we have seen over the last 20 years-30 years, I was asked this question 20 years ago about China as a serious generic threat, which never materialized, right? While China became the API hub of the world, 90% of APIs coming from there, it never materialized as a generic threat.
China, I think, has been is historically reluctant to be a frontrunning partner in the Western world, in Europe or in the U.S. for multiple reasons, with Chinese companies. And I don't think that's going to change. The base case is likely to be the same. So they're likely looking for partners. And if there's scope for us to partner, we'll partner. But otherwise, I don't expect to see a flood of biotech companies on the biologics side, biosimilar side, from China.
Okay. That's clear. Just to touch a bit on your long-term margin profile, sorry. 2025 guidance suggests an EBITDA margin, you know, roughly in the mid-30s%.
Mm-hmm.
You have 2028 aspiration, you know, roughly sort of 40%-45% EBITDA margin. So how should we think about the long-term margin potential for Alvotech and what could be sort of peak margin in the long term?
Okay. I won't call out a peak margin because that would be limiting ourselves. No, we'll definitely continue to strive to improve margins every year. We have just started on this journey last year of being profitable on the EBITDA side and generating this EBITDA. And we would expect this to be the case for the distant future too, right? As more and more products enter the markets globally in the U.S., we would expect to see margins expanding. 2028, again, we will be more precise because around 2028 there. But inherently, I think that as our products expand, we get great economies of scale. We have presence in more geographies and more countries. And especially as we get into the buy-and-bill side too. So we'll expect to see margin improvement consistently, yeah?
But beyond that, I think we'll give greater color on 2028 or definitely on the peak margins. We'll strive to continue to improve.
Amazing. Thank you, and then I want to also talk about the sort of process to select the biosimilar opportunities.
Yeah.
Can you run us through the sort of, you know, key consideration that you have when you select biosimilar opportunities and the balance between, you know, the size of the drug and also the competition risk that comes with it?
Sure. Maybe before responding to that question, I want to call out our Chief Scientific Officer, Joe McClellan , who I think was an extremely impressive person, who was, who has an amazing team with him. And he's been one of the drivers for us to be in this position where we are today. And so that's, that's really the thing, right? Being able to identify assets that in seven, eight years from now could be material and starting development work on it, which explains why on some of the assets like biosimilar Entyvio, even Eylea high-dose, or biosimilar Simponi, we see limited competition or no competition. And it is this, this astuteness, which is born out of decades of experience in the industry, that, that has got us to this spot. And so I just wanted to especially call out Joe and his team there.
That's one of the key drivers, right? Then, what are the other factors? Obviously, the total addressable market, the opportunity size, that matters a lot. And who else do we expect to be in competition for that? If we think that one, $1.5 billion biologic drug will see 10 players because the technology is not that prohibitive, then we are not likely to work on it. But if we think that even $1.5 billion product could be one where we have a technology edge and we can be in the market before or ahead of others, we'll definitely work on it. And that's really how we would think about it. And last point, again, because we are a global partnership model, we also have to think about the attractiveness of these assets to our partners too.
Okay. That's, that's clear. On the CapEx side, so the CapEx intensity for the company right now is very light.
Mm-hmm.
Considering that, you know, you're primarily an R&D and manufacturing business. So how far can your current capacity carry you, in terms of manufacturing, you know, the biosimilars? And should we expect at some point another CapEx cycle to increase the capacity?
Yeah. For the benefit of those following this conversation, what we have put out in terms of guidance for CapEx is around $70 million for 2025. And the next couple of years is around approximately $25 million per year for the next few years after 2028 exchange. But we don't see any incremental need for capacity. It's around. We are telling you that we are very comfortable with capacity. We think that with the existing capacity, we can address both our current commercial products and future anticipated launches up to 2030 and beyond. That said, we also want to be future-ready, ready for a phase in 2030, 2032, and beyond where we will need more capacity. And we are constantly wargaming it and wargaming it. And we will plan for it and expand as and when needed.
Ties back to the earlier point that I said that we've already invested $2 billion over the last 10 years into the facility we have at Reykjavik. The CapEx investments have been done, and now it's a matter of generating the returns of those CapEx investments.
Okay. And maybe in the last sort of couple of minutes that we have, can you help us understand, and I think there's been a debate, in particular, from generic investors, the sort of shape of revenues, you know, for biosimilar products, maybe across regions, you know, is it sort of a ramp-up phase and we reach a peak and then we expect a decline? Does this depend on the geographic sort of split? And then when you take a product, you know, at Alvotech where you have multiple partners around the world, what does it mean for the shape of revenues for an opportunity?
Yeah. Again, glad that you asked the question too. I will take pains to stress that it's not a generic product lifecycle curve, where if you had a first-to-file or a 180-day exclusivity, you would have, like, bonanza in the first six months, and on day 181, it falls off the cliff. It is not that. So the biosimilars market is very different in its dynamics, for multiple reasons, primarily being the competitive landscape being much more sparse, right? I don't think the biosimilar Humira market has peaked. We would expect to see, after two years after all the biosimilars have entered, the biosimilar Humira market hasn't peaked. I think we will expect to see greater conversion in 2026 and possibly even 2027.
That we are now looking at possible market lifecycles of anywhere between 3 years-5 years for a product like that. And Stelara, as I said, first year, we are at 15%. We would expect this biosimilar conversion to go on as greater formulary exclusions come into place, just as we saw with biosimilar Humira this year. On July 1st, we saw the formulary exclusions take into effect. We'll see January 1st again. We'll see a similar dynamic. And as these things grow, addressing from a U.S. market, we will see this volume growth trend continue. Ex-U.S., it's going to be a volume growth story for the first few years, please. And as we introduce it into newer geographies, for us overall, the assets as a whole will still see volume growth too.
Amazing. We are at the end of the time. So, Balaji, thank you very much for your time and for joining us at the conference.
Thibault, well, thank you so much for the questions, and again, thank you, you and Morgan Stanley for inviting us to participate in the conference, and I wish you the very best. Thank you.